|
SBECD
| | | | | | | |
| |
Cmax (mg/L)
|
Cmin (mg/L)
|
T1/2 (hrs)
|
AUC0-12 (mg*hr/L)
|
Cls(L/hr/kg)
|
Vd (L/kg)
|
CVVH CL (L/hr/kg)
|
|
Mean
|
687.0
|
214.5
|
6.3
|
4396
|
0.03
|
0.3
|
0.02
|
|
SD
|
500.4
|
202.6
|
1.6
|
3325
|
0.02
|
0.2
|
0.01
|
|
Median
|
561.1
|
165.2
|
6.2
|
3621
|
0.02
|
0.2
|
0.01
|
|
25%
|
216.2
|
38.7
|
5.3
|
1352
|
0.01
|
0.1
|
0.01
|
|
75%
|
1102.4
|
305.8
|
7.3
|
6804
|
0.05
|
0.4
|
0.02
|
|
Voriconazole
| | | | | | | |
| |
Cmax (mg/L)
|
Cmin (mg/L)
|
T1/2 (hrs)
|
AUC0-12 (mg*hr/L)
|
Cls(L/hr/kg)
|
Vd (L/kg)
|
CVVH CL (L/hr/kg)
|
|
Mean
|
4.1
|
2.4
|
19.5
|
37
|
0.13
|
3.2
|
0.02
|
|
SD
|
1.4
|
1.1
|
10.7
|
14
|
0.06
|
1.5
|
0.02
|
|
Median
|
4.1
|
2.3
|
19.0
|
38
|
0.12
|
2.7
|
0.02
|
|
25%
|
3.3
|
2.0
|
13.1
|
30
|
0.09
|
2.1
|
0.01
|
|
75%
|
5.1
|
3.0
|
22.5
|
41
|
0.14
|
3.7
|
0.02
|
- SBECD, sulfobutylether-β-cyclodextrin; CVVH, continuous venovenous hemofiltration; Cmax, maximum drug concentration in the plasma; Cmin, minimum drug concentration in the plasma; T1/2, half-life; AUC0-12 area under the concentration-time curve from time 0 to 12 hours; Cls, total systemic clearance; Vd, volume of distribution; CVVH CL clearance by continuous venovenous hemofiltration; SD, standard deviation.
